A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical Solution

Completed · Phase 2

Conditions studied: Androgenetic Alopecia

In brief

Open label study to assess safety, tolerability, and efficacy of ATI-50002 in male and female subjects with androgenetic alopecia.

Key facts

Study ID: NCT03495817
Run by: Aclaris Therapeutics, Inc.
People needed: 31
Starts: 2018-03-22
Expected to finish: 2019-10-30
Last updated by the study team: 2020-12-09

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Male subjects and non-pregnant, non-nursing female subjects 18-50 years of age with a clinical diagnosis of androgenetic alopecia.
Subjects willing to agree to have a small circle of hair clipped to approx. 1mm in length on their balding spot.
Subjects willing to agree to have a permanent dot tattoo applied to their scalp to mark the center of the identified target area.
Subjects must agree to maintain the same hair style and hair care regimen during the study.

You may not qualify if…

Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.
Clinical diagnosis of alopecia areata or other non AGA forms of alopecia. Scalp hair loss on the treatment area, due to disease, injury or medical therapy.
Active skin disease of the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments or efficacy or safety.

Where it is running

Aclaris Investigational Site — Denver, Colorado, United States
Aclaris Investigational Site — Portland, Oregon, United States
Aclaris Investigational Site — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.